论文部分内容阅读
亚德里亚霉素(Adrimycin,又译阿霉素)广泛应用于临床癌症化疗中。它抗瘤谱广,对软组织瘤、乳癌、肺小细胞癌以及急性白血病均有效。不幸的是,在其临床应用中出现了副反应,其中尤以心脏毒性最为严重。累积剂量所致的心肌病变严重地限制了在肺瘤治疗中注射亚德里亚霉素的总剂量。因此,在不影响药物抗瘤活性的同时必须考虑预防其心脏毒性并获得相加的治疗效果。亚德里亚霉素引起的心肌细胞损伤包括
Adriamycin (Adrimycin) is widely used in clinical cancer chemotherapy. It is broad-spectrum anti-tumor, soft tissue tumors, breast cancer, small cell lung cancer and acute leukemia are effective. Unfortunately, there have been side effects in its clinical use, with the most serious cardiotoxicity. Cumulative dose-induced cardiomyopathy severely limits the total dose of adriamycin injected during the treatment of lung tumors. Therefore, without affecting the anti-tumor activity of the drug must be considered at the same time to prevent its cardiotoxicity and to obtain additive therapeutic effect. Adriamycin-induced cardiomyocyte damage includes